Tag: health policy anaysis

AUSTRALIA – CANCER DRUG REIMBURSEMENT ON PHASE 2 DATA

London, UK – Before a drug can be sold in Australia, it must receive approval from the regulator: the Therapeutic Goods Administration (TGA), typically requiring data from a large and lengthy Phase 3 randomized clinical trial. Public funding additionally requires

Posted in Health Policy Analyses Tagged with: , , ,

ENSURING THE FUTURE FOR CHINA’S ESSENTIAL DRUG POLICY

New Orleans, LA, USA & Shandong, China – China is one of the few middle-income countries with higher pharmaceutical cost out of total health care spending. The primary purpose of China’s National Essential Drug Policy (NEDP) in year 2009 was

Posted in Health Policy Analyses, Value in Health Regional Issues Tagged with: , , ,